Guilin Sanjin Pharmaceutical Co., Ltd. (SHE:002275)
14.27
-0.02 (-0.14%)
At close: Feb 3, 2026
SHE:002275 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 2,080 | 2,192 | 2,168 | 1,954 | 1,739 | 1,564 |
Other Revenue | 1.76 | 1.76 | 3.66 | 5.27 | 2.71 | 2.79 |
| 2,082 | 2,194 | 2,172 | 1,960 | 1,741 | 1,566 | |
Revenue Growth (YoY) | -1.56% | 1.03% | 10.81% | 12.55% | 11.15% | -4.51% |
Cost of Revenue | 576.55 | 610.47 | 602.57 | 574.37 | 457.04 | 449.25 |
Gross Profit | 1,505 | 1,584 | 1,569 | 1,385 | 1,284 | 1,117 |
Selling, General & Admin | 825.1 | 888.26 | 920.66 | 812.68 | 722.13 | 628.74 |
Research & Development | 149.5 | 173.29 | 158.06 | 217.04 | 201.6 | 147.56 |
Other Operating Expenses | 61.96 | 32.28 | 29.89 | 36.09 | 32.8 | 30.4 |
Operating Expenses | 1,050 | 1,103 | 1,109 | 1,070 | 957.81 | 803.92 |
Operating Income | 454.88 | 480.47 | 460.41 | 315.65 | 326.37 | 313.31 |
Interest Expense | -8.79 | -13.84 | -16.36 | -20.24 | -18.21 | -11.55 |
Interest & Investment Income | 44.5 | 34.4 | 33.17 | 40.64 | 39.8 | 29.41 |
Currency Exchange Gain (Loss) | 0.19 | 0.19 | -0.08 | -3.59 | 0.57 | 0.01 |
Other Non Operating Income (Expenses) | -8.08 | -0.25 | 0.05 | -0.58 | -1.23 | -0.14 |
EBT Excluding Unusual Items | 482.7 | 500.97 | 477.2 | 331.89 | 347.31 | 331.05 |
Gain (Loss) on Sale of Investments | 8.4 | 4.65 | 1.19 | 0.16 | 1.77 | -1.37 |
Gain (Loss) on Sale of Assets | 79.23 | 83.36 | 1.67 | 31.26 | 15.5 | - |
Asset Writedown | 2.21 | -0.86 | -0.17 | -1.02 | -8.12 | -1.71 |
Other Unusual Items | 75.96 | 55.82 | 38.39 | 83.89 | 72.61 | 16.2 |
Pretax Income | 648.49 | 643.93 | 518.28 | 446.18 | 429.06 | 344.17 |
Income Tax Expense | 125.61 | 122.4 | 96.99 | 116.65 | 85.34 | 67.14 |
Net Income | 522.88 | 521.53 | 421.3 | 329.53 | 343.72 | 277.02 |
Net Income to Common | 522.88 | 521.53 | 421.3 | 329.53 | 343.72 | 277.02 |
Net Income Growth | 28.07% | 23.79% | 27.85% | -4.13% | 24.08% | -29.36% |
Shares Outstanding (Basic) | 581 | 586 | 585 | 588 | 573 | 577 |
Shares Outstanding (Diluted) | 581 | 586 | 585 | 588 | 573 | 577 |
Shares Change (YoY) | -1.61% | 0.15% | -0.56% | 2.72% | -0.74% | -1.39% |
EPS (Basic) | 0.90 | 0.89 | 0.72 | 0.56 | 0.60 | 0.48 |
EPS (Diluted) | 0.90 | 0.89 | 0.72 | 0.56 | 0.60 | 0.48 |
EPS Growth | 30.16% | 23.61% | 28.57% | -6.67% | 25.00% | -28.36% |
Free Cash Flow | 579.5 | 506.16 | 472.85 | 466.4 | 266.15 | 392.52 |
Free Cash Flow Per Share | 1.00 | 0.86 | 0.81 | 0.79 | 0.47 | 0.68 |
Dividend Per Share | 0.550 | 0.600 | 0.600 | 0.800 | 0.900 | 0.400 |
Dividend Growth | - | - | -25.00% | -11.11% | 125.00% | 73.91% |
Gross Margin | 72.30% | 72.17% | 72.25% | 70.69% | 73.75% | 71.32% |
Operating Margin | 21.85% | 21.90% | 21.20% | 16.11% | 18.74% | 20.00% |
Profit Margin | 25.12% | 23.77% | 19.40% | 16.81% | 19.74% | 17.68% |
Free Cash Flow Margin | 27.84% | 23.07% | 21.77% | 23.80% | 15.29% | 25.06% |
EBITDA | 527.7 | 571.42 | 575.53 | 412.21 | 412.97 | 393.58 |
EBITDA Margin | 25.35% | 26.05% | 26.50% | 21.03% | 23.72% | 25.12% |
D&A For EBITDA | 72.83 | 90.95 | 115.12 | 96.55 | 86.6 | 80.27 |
EBIT | 454.88 | 480.47 | 460.41 | 315.65 | 326.37 | 313.31 |
EBIT Margin | 21.85% | 21.90% | 21.20% | 16.11% | 18.74% | 20.00% |
Effective Tax Rate | 19.37% | 19.01% | 18.71% | 26.15% | 19.89% | 19.51% |
Revenue as Reported | 2,082 | 2,194 | 2,172 | 1,960 | 1,741 | 1,566 |
Advertising Expenses | - | 530.36 | 514.72 | 361.86 | 378.93 | 64.35 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.